Your browser doesn't support javascript.
loading
Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
Ooi, Chee Y; Sutherland, Rosie; Castellani, Carlo; Keenan, Katherine; Boland, Margaret; Reisman, Joe; Bjornson, Candice; Chilvers, Mark A; van Wylick, Richard; Kent, Steven; Price, April; Mateos-Corral, Dimas; Hughes, Daniel; Solomon, Melinda; Zuberbuhler, Peter; Brusky, Janna; Durie, Peter R; Ratjen, Felix; Gonska, Tanja.
Afiliação
  • Ooi CY; Discipline of Paediatrics, School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia. Keith.Ooi@unsw.edu.au.
  • Sutherland R; miCF Research Centre and Department of Gastroenterology, Sydney Children's Hospital Randwick, High Street, Randwick NSW, Sydney, Australia. Keith.Ooi@unsw.edu.au.
  • Castellani C; Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada. Keith.Ooi@unsw.edu.au.
  • Keenan K; Discipline of Paediatrics, School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.
  • Boland M; Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Reisman J; Physiology and Experimental Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Bjornson C; Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Eastern Ontario, Ottawa, Canada.
  • Chilvers MA; Department of Paediatrics, Division of Respirology, Children's Hospital of Eastern Ontario, Ottawa, Canada.
  • van Wylick R; Department of Pediatrics, Section of Respiratory Medicine, University of Calgary, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Kent S; Department of Pediatrics, Division of Pediatric Respiratory Medicine, BC Childrens Hospital, Vancouver, BC, Canada.
  • Price A; Department of Pediatrics, School of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Mateos-Corral D; Victoria General Hospital, Victoria, BC, Canada.
  • Hughes D; Children's Hospital Of Western Ontario, London, Ontario, Canada.
  • Solomon M; IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Zuberbuhler P; IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Brusky J; Department of Paediatrics, Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada.
  • Durie PR; Stollery Children's Hospital, Edmonton, Alberta, Canada.
  • Ratjen F; Royal University Hospital, Saskatoon, Saskatchewan, Canada.
  • Gonska T; Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
BMC Pediatr ; 19(1): 369, 2019 10 22.
Article em En | MEDLINE | ID: mdl-31640630
ABSTRACT

BACKGROUND:

Newborn screening (NBS) for cystic fibrosis (CF) not only identifies infants with a diagnosis of CF, but also those with an uncertain diagnosis of cystic fibrosis (CF), i.e. CF transmembrane conductance regulator (CFTR)-related metabolic syndrome (CRMS) or CF screen positive inconclusive diagnosis (CFSPID). These infants have an uncertain long-term outcome and it is currently unclear around time of diagnosis, which infants are at higher risk of later fulfilling a CF diagnosis. In this study, we hypothesised that immunoreactive trypsinogen (IRT) levels, used in NBS as a marker of pancreatic disease and function, may reflect the degree of CFTR dysfunction in each individual and therefore would help to identify those with CRMS/CSPID who are later at risk for meeting the criteria of CF.

METHODS:

In this longitudinal, prospective study, infants with CRMS/CFSPID and CF were recruited and followed in 9 CF clinics (Canada and Italy). We compared NBS IRT levels between CF and CRMS/CFSPID, and between children with CRMS/CFSPID→CF and CRMS/CFSPID→CRMS/CFSPID during the period of June 2007 to April 2016.

RESULTS:

Ninety eight CRMS/CFSPID and 120 CF subjects were enrolled. During the study period, 14 (14.3%) CRMS/CFSPID subjects fulfilled the diagnostic criteria for CF (CRMS/CFSPID→CF), while the diagnosis remained uncertain (CRMS/CFSPID→ CRMS/CFSPID) in 84 (85.7%) subjects. Significantly higher NBS IRT concentrations (ng/ml) were present in CF than CRMS/CFPSID (median (interquartile range) 143.8 (99.8-206.2) vs. 75.0 (61.0-105.9); P < 0.0001). Infants with CRMS/CFSPID→CF (n = 14) had significantly higher NBS IRT concentrations (ng/ml) than CRMS/CFSPID→ CRMS/CFSPID (n = 83) (median (interquartile range) 108.9 (72.3-126.8) vs. 73.7(60.0-96.0); P = 0.02).

CONCLUSIONS:

Amongst infants who tested positive on NBS for CF, there is a gradation of elevated NBS IRT concentrations. Infants with CF have higher NBS IRT levels than CRMS/CFPSID, and higher NBS IRT concentrations were present in infants with CRMS/CFSPID→CF than CRMS/CFSPID→ CRMS/CFSPID. NBS IRT concentrations, in concert with other factors, may have the potential to predict the likelihood of CF amongst infants with CRMS/CFSPID.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tripsinogênio / Triagem Neonatal / Fibrose Cística Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Newborn Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tripsinogênio / Triagem Neonatal / Fibrose Cística Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Newborn Idioma: En Ano de publicação: 2019 Tipo de documento: Article